

# Julia S Johansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4415190/publications.pdf>

Version: 2024-02-01

115  
papers

5,123  
citations

126907

33  
h-index

91884

69  
g-index

117  
all docs

117  
docs citations

117  
times ranked

8502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial. <i>Oncologist</i> , 2022, 27, 67-78.	3.7	30
2	Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 554-554.	1.6	1
3	Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 819.	3.7	17
4	Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4144.	4.1	11
5	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 3180-3189.	1.6	29
6	Abstract 523: Type XX collagen is elevated in circulation of patients with solid tumors and high levels are associated with higher overall mortality in pancreatic cancer. <i>Cancer Research</i> , 2022, 82, 523-523.	0.9	2
7	Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. <i>Journal of Hepatology</i> , 2022, 77, 1047-1058.	3.7	7
8	The potential use of blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4082-4082.	1.6	0
9	Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. <i>Cancers</i> , 2022, 14, 3250.	3.7	4
10	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related <sc><i>RAS</i></sc> and <sc><i>BRAF</i></sc> mutation status. <i>International Journal of Cancer</i> , 2021, 148, 2542-2556.	5.1	4
11	Geriatric assessment and intervention in older vulnerable patients undergoing surgery for colorectal cancer: a protocol for a randomised controlled trial (GEPOC trial). <i>BMC Geriatrics</i> , 2021, 21, 88.	2.7	18
12	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2021, 144, 72-80.	2.8	17
13	Noninvasive prognostic biomarker potential of quantifying the propeptides of <sc>Type XI</sc> collagen alpha€1 chain (<sc>PRO€11</sc>) in patients with pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021, 149, 228-238.	5.1	21
14	Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. <i>Clinical Cancer Research</i> , 2021, 27, 2592-2603.	7.0	14
15	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. <i>Scientific Reports</i> , 2021, 11, 7570.	3.3	2
16	Genome-wide cfDNA fragmentation in patients with cancer and other diseases.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3136-3136.	1.6	1
17	Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4599.	3.7	5
18	Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma €€ An external validation study. <i>Pancreatology</i> , 2021, 21, 1081-1091.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab. Scientific Reports, 2021, 11, 865.	3.3	16
20	Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer, 2021, 158, 248-250.	2.8	0
21	Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. International Journal of Cancer, 2020, 146, 2913-2922.	5.1	41
22	Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 176-184.	2.5	12
23	Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. European Journal of Cancer Care, 2020, 29, e13219.	1.5	19
24	Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8â€“12â€“years of follow-up. International Journal of Cancer, 2020, 146, 2019-2026.	5.1	14
25	Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases. PLoS ONE, 2020, 15, e0236569.	2.5	14
26	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. Clinical Cancer Research, 2020, 26, 5655-5667.	7.0	21
27	Prognostic biomarker potential of quantifying endotrophin in serum from pancreas cancer patients.. Journal of Clinical Oncology, 2020, 38, e16804-e16804.	1.6	0
28	Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	6
29	Title is missing!. , 2020, 15, e0236569.		0
30	Title is missing!. , 2020, 15, e0236569.		0
31	Title is missing!. , 2020, 15, e0236569.		0
32	Title is missing!. , 2020, 15, e0236569.		0
33	Title is missing!. , 2020, 15, e0236569.		0
34	Title is missing!. , 2020, 15, e0236569.		0
35	Title is missing!. , 2020, 15, e0236569.		0
36	Title is missing!. , 2020, 15, e0236569.		0

#	ARTICLE	IF	CITATIONS
37	Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. <i>European Journal of Cancer</i> , 2019, 121, 74-84.	2.8	3
38	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	27.8	764
39	Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?. <i>Acta Oncol<sup>3</sup>gica</i> , 2019, 58, S42-S48.	1.8	1
40	Genome-wide cell-free DNA fragmentation profiling for early cancer detection.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3018-3018.	1.6	1
41	Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial. <i>Journal of Rheumatology</i> , 2018, 45, 53-61.	2.0	35
42	Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	3.0	52
43	Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2887-2894.	1.6	108
44	Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. <i>Oncotarget</i> , 2018, 9, 29820-29841.	1.8	107
45	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881120.	1.8	10
46	Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study. <i>Acta Oncol<sup>3</sup>gica</i> , 2018, 57, 1445-1454.	1.8	16
47	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. <i>Translational Oncology</i> , 2018, 11, 1220-1224.	3.7	63
48	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <i>British Journal of Cancer</i> , 2018, 118, 1609-1616.	6.4	47
49	Prognostic evaluation of a new class of liquid biopsy biomarkers in patients with metastatic colorectal cancer: Using the tumor microenvironment as a source of protein biomarkers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3588-3588.	1.6	6
50	Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. <i>Oncotarget</i> , 2018, 9, 6752-6762.	1.8	21
51	Prognostic value of serum interleukin-6 and YKL-40 and systemic inflammatory response in patients with unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 267-267.	1.6	0
52	Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16249-e16249.	1.6	1
53	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. <i>European Journal of Cancer</i> , 2017, 81, 26-35.	2.8	13
54	Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. <i>Biomarker Research</i> , 2017, 5, 8.	6.8	48

#	ARTICLE	IF	CITATIONS
55	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2017, 22, 1049-1055.	3.7	73
56	The prognostic value of serum CA 19-9 in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15131-e15131.	1.6	1
57	Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 97769-97786.	1.8	28
58	The prognostic value of serum IL-6 and YKL-40 in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15060-e15060.	1.6	0
59	The prognostic value of serum IL-6 and YKL-40 in colorectal cancer patients before liver resection.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15078-e15078.	1.6	0
60	The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. <i>Cardiovascular Endocrinology</i> , 2016, 5, 21-27.	0.8	4
61	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. <i>Nature Medicine</i> , 2016, 22, 497-505.	30.7	456
62	Serum YKL-40 and gestational diabetes – an observational cohort study. <i>Apmis</i> , 2016, 124, 770-775.	2.0	8
63	The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. <i>International Journal of Cancer</i> , 2016, 139, 2312-2324.	5.1	33
64	Observationally and Genetically High YKL-40 and Risk of Venous Thromboembolism in the General Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1030-1036.	2.4	18
65	Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer <sup>&gt;=&lt;/sup&gt;. <i>Scandinavian Journal of Gastroenterology</i>, 2016, 51, 860-865.</sup>	1.5	8
66	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 75013-75022.	1.8	61
67	Prognostic impact of plasma CA 19-9, IL-6 and YKL-40 in patients with inoperable cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15638-e15638.	1.6	0
68	Prediction of unresectability and overall survival in patients with pancreatic cancer using preoperative plasma CA 19.9, IL-6 and YKL-40.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15689-e15689.	1.6	0
69	YKL-40 and genetic status of <i>CHI3L1</i> in a large group of asthmatics. <i>European Clinical Respiratory Journal</i> , 2015, 2, 25117.	1.5	13
70	Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies. <i>Biomarkers in Cancer</i> , 2015, 7, BIC.S31330.	3.6	7
71	Observational and genetic plasma <i>YKL-40</i> and cancer in 96,099 individuals from the general population. <i>International Journal of Cancer</i> , 2015, 137, 2696-2704.	5.1	20
72	Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2650-2659.	1.3	17

#	ARTICLE	IF	CITATIONS
73	Serum YKL-40 in Risk Assessment for Colorectal Cancer: A Prospective Study of 4,496 Subjects at Risk of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 621-626.	2.5	45
74	Plasma YKL-40 in Inuit and Danes. <i>Alcohol and Alcoholism</i> , 2015, 50, 11-17.	1.6	3
75	Elevated Plasma YKL-40, Lipids and Lipoproteins, and Ischemic Vascular Disease in the General Population. <i>Stroke</i> , 2015, 46, 329-335.	2.0	45
76	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	12.8	393
77	Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality – a cohort study. <i>Journal of Inflammation</i> , 2015, 12, 20.	3.4	42
78	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015, 64, 921-928.	12.1	22
79	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015, 51, 2678-2685.	2.8	48
80	Circulating tumor necrosis factor- $\alpha$ and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2476-2478.	1.3	7
81	Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4021-4021.	1.6	2
82	Comparative circulating tumor DNA levels for KRAS mutations in patients with nonresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 288-288.	1.6	2
83	Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4022-4022.	1.6	1
84	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3548-3548.	1.6	0
85	miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e99886.	2.5	68
86	YKL-40 and Alcoholic Liver and Pancreas Damage and Disease in 86258 Individuals from the General Population: Cohort and Mendelian Randomization Studies. <i>Clinical Chemistry</i> , 2014, 60, 1429-1440.	3.2	16
87	MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 392.	7.4	380
88	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. <i>PLoS ONE</i> , 2014, 9, e87746.	2.5	18
89	Antibody Directed against Human YKL-40 Increases Tumor Volume in a Human Melanoma Xenograft Model in Scid Mice. <i>PLoS ONE</i> , 2014, 9, e95822.	2.5	14
90	Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. <i>PLoS ONE</i> , 2014, 9, e109430.	2.5	39

#	ARTICLE	IF	CITATIONS
91	The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 1176-1176.	1.4	0
92	Genetic variants in <i>CHI3L1</i> influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population. Journal of Medical Genetics, 2013, 50, 831-837.	3.2	17
93	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3572-3572.	1.6	2
94	Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers.. Journal of Clinical Oncology, 2013, 31, 164-164.	1.6	1
95	MicroRNA biomarkers in whole blood for detection of pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 4052-4052.	1.6	2
96	The prognostic value of seven soluble proteins measured in plasma or serum from patients with colorectal cancer in TNM stages I-III.. Journal of Clinical Oncology, 2012, 30, 35-35.	1.6	1
97	Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.. Journal of Clinical Oncology, 2012, 30, 451-451.	1.6	1
98	Diagnostic microRNA serum profile in pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 160-160.	1.6	0
99	Plasma concentrations of YKL-40 in chemo-naïve patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2012, 30, 3548-3548.	1.6	0
100	Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.. Journal of Clinical Oncology, 2012, 30, 8545-8545.	1.6	0
101	Plasma YKL-40 and Total and Disease-Specific Mortality in the General Population. Clinical Chemistry, 2010, 56, 1580-1591.	3.2	57
102	Plasma YKL-40: a potential new cancer biomarker?. Future Oncology, 2009, 5, 1065-1082.	2.4	137
103	Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population. Journal of Clinical Oncology, 2009, 27, 572-578.	1.6	76
104	Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2603-2608.	2.5	63
105	Is YKL-40 a new therapeutic target in cancer?. Expert Opinion on Therapeutic Targets, 2007, 11, 219-234.	3.4	48
106	YKL-40 Protein Expression in the Early Developing Human Musculoskeletal System. Journal of Histochemistry and Cytochemistry, 2007, 55, 1213-1228.	2.5	86
107	Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival. Clinical Cancer Research, 2007, 13, 3244-3249.	7.0	51
108	Serum YKL-40, A New Prognostic Biomarker in Cancer Patients?. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 194-202.	2.5	265

#	ARTICLE	IF	CITATIONS
109	Increased serum YKL-40 in patients with pulmonary sarcoidosisâ€”a potential marker of disease activity?. Respiratory Medicine, 2005, 99, 396-402.	2.9	86
110	High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer, 2004, 46, 333-340.	2.0	116
111	YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis and Rheumatism, 1999, 42, 2624-2630.	6.7	89
112	Identification of proteins secreted by human osteoblastic cells in culture. Journal of Bone and Mineral Research, 1992, 7, 501-512.	2.8	231
113	The effect of growth hormone (GH) therapy on urinary pyridinoline crossâ€”links in GHâ€”deficient adults. Clinical Endocrinology, 1991, 35, 471-476.	2.4	101
114	Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. European Journal of Clinical Investigation, 1988, 18, 191-195.	3.4	160
115	Bone Metabolism and Bone Status in Osteoporotic Patients. Acta Medica Scandinavica, 1987, 222, 453-458.	0.0	11